Hepatitis B Virus (HBV)

Tag: HMG-CoA reductase inhibitors (Page 2)

Atorvastatin calcium: PLACE IN THERAPY(4)

In recent years, the use of higher doses of HMG-CoA reductase inhibitors has been investigated in attempts to achieve greater reductions in plasma LDL-C levels, probably as a result of the evidence from the landmark studies. The WOSCOPS and CARE trials were conducted with the maximum approved dose of pravastatin (40 mg/day) . While 63% […]

Atorvastatin calcium: PLACE IN THERAPY(3)

There are reasons to believe that greater benefits in CAD morbidity and mortality can be achieved with greater reductions in LDL-C levels. Meta-analysis of clinical trials data, including the recent data with HMG-CoA reductase inhibitors, demonstrates that the magnitude of benefit (lower CAD morbidity and mortality and total mortality risk) is directly related to the […]

Atorvastatin calcium: PLACE IN THERAPY(2)

Of all the available treatment options for the management of elevated lipid levels, HMG-CoA reductase inhibitors have provided the strongest evidence yet that lowering plasma LDL-C level is accompanied with reduced risk of developing cardiovascular events and death from cardiovascular events . Although, as discussed earlier, there are animal data and some data in humans […]

Atorvastatin calcium: PLACE IN THERAPY(1)

Because the link between CAD and cholesterol has been clinically demonstrated and widely accepted, many approaches to addressing cholesterol have been explored. While efforts aimed at public education that target diet and exercise have made a positive impact on CAD, lifestyle pressures appear to cause a large number of patients to fail to reach target […]

Atorvastatin calcium: FUTURE STUDIES(2)

Another end-point trial, Treat to New Targets (TNT), isde-signed to test whether additional benefit in cardiovascular risk reduction is achieved by treating CAD patients to target LDL-C levels below 2.6 mmol/L with atorvastatin (personal communication). This five-year worldwide study involving 8600 patients will be one of the largest outcome trials ever conducted with a cholesterol-lowering […]

Atorvastatin calcium: FUTURE STUDIES(1)

Studies evaluating the outcomes of atorvastatin treatment in cardiovascular events are underway. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study is evaluating whether aggressive lipid lowering with atorvastatin commenced in the first few days following an acute coronary event effectively reduces the recurrence of subsequent ischemic events in patients with unstable angina or […]

Atorvastatin calcium: OTHER ACTIONS

In a three-month study in hyperlipidemic patients, atorva-statin-induced reductions in lipoprotein levels (LDL-C, triglycerides, VLDL-C) were accompanied by significant changes in hemorheology and atherothrombotic parameters . Plasma viscosity, factor VII activity and red blood cell sedimentation were significantly reduced in all patients; however, these changes were most evident for patients with type IIb dyslipidemia. These […]